MedTrace Logo

New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis

NCT00244179 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-09-08

No results posted yet for this study

Summary

1. to investigate, whether one of the two alternative therapy strategies (antibiotic plus immunostimulation versus antibiotic plus immunosuppression) in chronic reactive arthritis is therapeutical superior to conventionel standardtherapy (DMARD).
2. to investigate, whether one or more of the different therapy strategies cause an altered detection of bacterial DNA in the joint or colon.
3. to measure the antigen-specific and -unspecific immune response (predominantly t-cell response) during therapy and correlate it with the clinical course.
4. to gain knowledge from these analyses and the clinical course concerning the pathogenesis and the point of attack for possible therapies in chronic reactive arthritis.
5. to compare cytokine-profiles of CD4- and CD8-positive T-cells from patients treated with infliximab to those treated with etanercept.

Conditions

  • Reactive Arthritis

Interventions

DRUG

interferon-gamma

DRUG

infliximab

DRUG

dmard

Sponsors & Collaborators

  • dfg

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • joachim sieper, prof. · charite, campus benjamin franklin, rheumatology, berlin

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244179 on ClinicalTrials.gov